[go: up one dir, main page]

PE20081256A1 - Triazalopiridacina como modulador de la actividad proteina cinasa - Google Patents

Triazalopiridacina como modulador de la actividad proteina cinasa

Info

Publication number
PE20081256A1
PE20081256A1 PE2007001436A PE2007001436A PE20081256A1 PE 20081256 A1 PE20081256 A1 PE 20081256A1 PE 2007001436 A PE2007001436 A PE 2007001436A PE 2007001436 A PE2007001436 A PE 2007001436A PE 20081256 A1 PE20081256 A1 PE 20081256A1
Authority
PE
Peru
Prior art keywords
halogen
triazalopyridacine
modulator
protein kinase
kinase activity
Prior art date
Application number
PE2007001436A
Other languages
English (en)
Inventor
Christopher Ronald Smith
Pierre-Yves Bounaud
Elizabeth Anne Jefferson
Patrick S Lee
Eduardo Torres
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of PE20081256A1 publication Critical patent/PE20081256A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

REFERIDA A UN DERIVADO DE TRIAZALOPIRIDACINA DE FORMULA (I), DONDE A ES UN GRUPO ARILO O HETEROARILO; Q ES H, HALOGENO, AMINO, PERFLUOROALQUILO, ENTRE OTROS; T ES CH2, CH(HALOGENO), C(HALOGENO), ENTRE OTROS; X ES N O CR2; R1 Y R2 SON H, HALOGENO, NITRO, CIANO, OH, ENTRE OTROS; R28' Y R28'' SON H, HALOGENO, NITRO, CIANO, ENTRE OTROS; R35 ES UN ENLACE, H, HALOGENO, NITRO, OH, ENTRE OTROS; z ES UN ENTERO DE 0 A 3. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DE LA TIROSINA CINASAS, PARTICULARMENTE, MET Y SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2007001436A 2006-10-23 2007-10-23 Triazalopiridacina como modulador de la actividad proteina cinasa PE20081256A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87138406P 2006-12-21 2006-12-21
US91375207P 2007-04-24 2007-04-24
US95283307P 2007-07-30 2007-07-30

Publications (1)

Publication Number Publication Date
PE20081256A1 true PE20081256A1 (es) 2008-10-13

Family

ID=39031065

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001436A PE20081256A1 (es) 2006-10-23 2007-10-23 Triazalopiridacina como modulador de la actividad proteina cinasa

Country Status (16)

Country Link
US (1) US8071581B2 (es)
EP (1) EP2081937B1 (es)
JP (1) JP2010507577A (es)
KR (1) KR101083177B1 (es)
AU (1) AU2007309237B2 (es)
BR (1) BRPI0717317A2 (es)
CA (1) CA2667453A1 (es)
DK (1) DK2081937T3 (es)
EA (1) EA016527B1 (es)
ES (1) ES2393132T3 (es)
MX (1) MX2009004060A (es)
PE (1) PE20081256A1 (es)
PL (1) PL2081937T3 (es)
PT (1) PT2081937E (es)
TW (1) TW200833692A (es)
WO (1) WO2008051805A2 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP3091011B1 (en) 2006-04-07 2017-12-27 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
JP5572388B2 (ja) 2006-11-22 2014-08-13 インサイト・コーポレイション キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
JP6022158B2 (ja) * 2008-05-21 2016-11-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ２−フルオロ−Ｎ−メチル−４−［７−（キノリン−６−イル−メチル）−イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの塩及びそれを調製することに関する方法
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
EP2356116A1 (en) * 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
AU2009325072A1 (en) 2008-12-12 2011-06-30 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
DE102008063667A1 (de) * 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
SG172986A1 (en) * 2009-02-10 2011-08-29 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
US8865719B2 (en) 2009-03-09 2014-10-21 The Regents Of The University Of California Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
ES2927146T3 (es) * 2009-12-31 2022-11-02 Hutchison Medipharma Ltd Ciertas triazolopirazinas, composiciones de estas y sus métodos de empleo
ES2608329T3 (es) 2010-02-03 2017-04-07 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG10201505700QA (en) * 2010-04-22 2015-08-28 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
DK2571878T3 (en) 2010-05-17 2019-02-11 Indian Incozen Therapeutics Pvt Ltd Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES
US8513291B2 (en) * 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
AU2012314501B2 (en) 2011-09-27 2017-02-16 Genfit Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
CN107082779A (zh) 2012-03-30 2017-08-22 理森制药股份公司 作为c‑met 蛋白激酶调节剂的新化合物
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
CN103122000B (zh) 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
BR112015008515A2 (pt) 2012-10-16 2017-07-04 Janssen Pharmaceutica Nv moduladores de ror t de quinolinila ligada à heteroarila
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
AU2013331496B2 (en) 2012-10-16 2017-07-27 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ROR-gamma-t
US9846345B2 (en) 2013-02-28 2017-12-19 Empire Technology Development Llc Colored pigment particles for electrophoretic displays
CN108929333A (zh) * 2013-03-13 2018-12-04 豪夫迈·罗氏有限公司 制备苯并氧氮杂*化合物的方法
RU2680100C9 (ru) 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
US20140303121A1 (en) * 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
EP3057422B1 (en) 2013-10-15 2019-05-15 Janssen Pharmaceutica NV Quinolinyl modulators of ror(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015134854A2 (en) * 2014-03-06 2015-09-11 Oyagen, Inc. Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3180335B1 (en) 2014-08-11 2021-05-05 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
US10287282B2 (en) 2014-12-31 2019-05-14 Angion Biomedica Corp. Methods and agents for treating disease
HUE053903T2 (hu) * 2015-04-13 2021-07-28 Five Prime Therapeutics Inc Kombinációs terápia rák ellen
IL305843B2 (en) 2015-07-20 2025-01-01 Genzyme Corp CSF-1R receptor antibodies
CA3079029A1 (en) 2017-10-13 2019-04-18 Plexxikon Inc. Solid forms of a compound for modulating kinases
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN113861198B (zh) * 2020-06-30 2024-08-02 上海医药集团股份有限公司 咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960584B2 (en) * 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
JP4115390B2 (ja) * 2001-08-10 2008-07-09 よこはまティーエルオー株式会社 伝熱装置
WO2007075567A1 (en) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines as tyrosine kinase modulators
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso

Also Published As

Publication number Publication date
EP2081937A2 (en) 2009-07-29
PL2081937T3 (pl) 2013-01-31
WO2008051805A2 (en) 2008-05-02
PT2081937E (pt) 2012-10-15
KR101083177B1 (ko) 2011-11-11
WO2008051805A3 (en) 2008-07-10
ES2393132T3 (es) 2012-12-18
TW200833692A (en) 2008-08-16
EP2081937B1 (en) 2012-09-12
BRPI0717317A2 (pt) 2013-10-22
MX2009004060A (es) 2009-06-19
JP2010507577A (ja) 2010-03-11
AU2007309237A1 (en) 2008-05-02
EA016527B1 (ru) 2012-05-30
DK2081937T3 (da) 2012-10-01
AU2007309237B2 (en) 2012-03-22
US20100120739A1 (en) 2010-05-13
EA200970402A1 (ru) 2009-10-30
US8071581B2 (en) 2011-12-06
KR20090069303A (ko) 2009-06-30
CA2667453A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
PE20081256A1 (es) Triazalopiridacina como modulador de la actividad proteina cinasa
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
EA200601785A1 (ru) Соединения и способы лечения дислипидемии
EA200700119A1 (ru) Соединения и способы лечения дислипидемии
CY1113560T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
UY28936A1 (es) Grupo de compuestos benzoil-amino-heterociclilo y composiciones farmaceuticas que los comprenden, utiles para tratamiento de enfermedades mediadas por glucoquinasa (gq)
PE20090229A1 (es) DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
EA201100873A1 (ru) Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания
BRPI0513310A (pt) análogos de tetrapeptìdeo
EA200971077A1 (ru) Гетероциклические модуляторы киназы
UY26695A1 (es) Activadores para amino sustituidos de la fenilamida glucoquinasa
PE20081262A1 (es) Derivados de fenilo como moduladores de cinasas y composiciones
ATE433447T1 (de) Pyrimiidinverbindungen
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
ATE447562T1 (de) Verstärker von glutamat-rezeptoren
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
CR9649A (es) Aminopirimidinas como modulares de cinasa
ECSP077997A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed